Long-term dupilumab treatment for 100 weeks reduces serum TARC and total IgE in patients with moderate-to-severe atopic dermatitis

Long-term dupilumab treatment for 100 weeks reduces serum TARC and total IgE in patients with moderate-to-severe atopic dermatitis